Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
Sunitinib . malate
40
CHF
CHF 40.00
In stock
AG-CR1-3707-M0011 mgCHF 40.00
AG-CR1-3707-M0055 mgCHF 80.00
AG-CR1-3707-M02525 mgCHF 120.00
AG-CR1-3707-M500500 mgCHF 340.00
| Product Details | |
|---|---|
| Synonyms | SU-11248 |
| Product Type | Chemical |
| Properties | |
| Formula |
C22H27FN4O2 . C4H6O5 |
| MW | 398.5 . 134.1 |
| CAS | 341031-54-7 |
| Purity Chemicals | ≥98% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO (10mg/ml) or ethanol. |
| Identity | Determined by 1H-NMR. |
| InChi Key | LBWFXVZLPYTWQI-IPOVEDGCSA-N |
| Smiles | O[C@@H](CC(O)=O)C([O-])=O.[H][N+](CC)(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Potent ATP-competitive and cell permeable multi-targeted receptor tyrosine kinase (RTK) inhibitor targeting VEGFR and PDGFR-β. Inhibits FLK1 (Ki=9nM), PDGFRβ (Ki=8nM) and FLT3. It is at least 10-fold selective for FLK1 and PDGFRβ over a variety of tyrosine kinases in a panel, including EGFR, Cdk2, Met, IGFR-1, Abl and Src.
- Inhibits the cellular receptor phosphorylation of FLT3, RET and CSF-1R.
- Also shown to inhibit c-Kit.
- Exhibits potent antiangiogenic and antitumor activity in multiple xenograft models.
Product References
- Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase: L. Sun, et al.; J. Med. Chem. 46, 1116 (2003)
- In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship: D. B. Mendel, et al.; Clin. Cancer Res. 9, 327 (2003)
- SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo: A.M. O'Farrell, et al.; Blood 101, 3597 (2003)
- Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors: J. Guo, et al.; Mol. Cancer. Ther. 5, 1007 (2006)
- Molecular basis for sunitinib efficacy and future clinical development: S. Faivre, et al.; Nat. Rev. Drug Discov. 6, 734 (2007)
- Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor: R. Roskoski; BBRC 356, 323 (2007)
Related Products
